Pathway candidateNCBI-verifiedprotein-coding

TET3

tet methylcytosine dioxygenase 3

NCBI Gene: 200424 Ensembl GeneCards UniProt: O43151

Pathway candidate — not linked to PFS or PSSD by any record here

TET3 is in the library because it belongs to the epigenetic regulation family. No study, report or commentary in the corpus names it, so a variant in TET3 is not, by itself, evidence of anything related to post-drug syndromes.

Gene summary

A protein-coding gene on chromosome 2 (epigenetic regulation). Enables RNA polymerase II cis-regulatory region sequence-specific DNA binding activity; methyl-CpG binding activity; and zinc ion binding activity. Involved in positive regulation of transcription by RNA polymerase II and protein O-linked glycosylation.

Source: NCBI Gene, accessed 2026-10-07.

Protein reference (UniProt)

Protein: Methylcytosine dioxygenase TET3
Function (excerpt): Dioxygenase that catalyzes the conversion of the modified genomic base 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC) and plays a key role in epigenetic chromatin reprogramming in the zygote following fertilization. Also mediates subsequent conversion of 5hmC into 5-formylcytosine (5fC), and conversion of 5fC to 5-carboxylcytosine (5caC). Conversion of 5mC into 5hmC, 5fC and 5caC probably constitutes the first step in cytosine demethylation (By similarity). Selectively binds to the promoter region of target genes and contributes to regulate the expression of numerous developmental genes. In zygotes, DNA demethylation occurs selectively in the paternal pronucleus before the first cell division, while the adjacent maternal pronucleus and certain paternally-imprinted loci are protected from this process. Participates in DNA demethylation in the paternal pronucleus by mediating conversion of 5mC into 5hmC, 5fC and 5caC.
Subcellular location: Nucleus; Cytoplasm; Chromosome.
Tissue specificity: Expressed in colon, muscle, adrenal gland and peripheral blood lymphocytes.
Associated conditions: Beck-Fahrner syndrome (BEFAHRS).

Source: UniProtKB/Swiss-Prot O43151, release 2026_03, licensed CC BY 4.0. This is the protein’s normal biology, not evidence about post-drug syndromes; associated conditions are inherited disorders of the gene, not PFS, PSSD or PRSD.

Why its pathway is in the library

Epigenetic persistence is the leading hypothesis for why post-drug syndromes endure after the drug is gone; chromatin regulators are therefore priority candidates in any persistence mechanism.

Written for the whole epigenetic regulation family, not for TET3 specifically.

Mentioned in 0 corpus records

No corpus record names TET3 directly yet. It is in the library because it sits in a pathway the corpus tracks (Epigenetic regulation).

Also in epigenetic regulation

All 130 genes

Browse by family on the gene families page.

Gene summary

Source: NCBI Gene, accessed 2026-10-07.

Protein reference (UniProt)

Protein: Methylcytosine dioxygenase TET3
Function (excerpt): Dioxygenase that catalyzes the conversion of the modified genomic base 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC) and plays a key role in epigenetic chromatin reprogramming in the zygote following fertilization. Also mediates subsequent conversion of 5hmC into 5-formylcytosine (5fC), and conversion of 5fC to 5-carboxylcytosine (5caC). Conversion of 5mC into 5hmC, 5fC and 5caC probably constitutes the first step in cytosine demethylation (By similarity). Selectively binds to the promoter region of target genes and contributes to regulate the expression of numerous developmental genes. In zygotes, DNA demethylation occurs selectively in the paternal pronucleus before the first cell division, while the adjacent maternal pronucleus and certain paternally-imprinted loci are protected from this process. Participates in DNA demethylation in the paternal pronucleus by mediating conversion of 5mC into 5hmC, 5fC and 5caC.
Subcellular location: Nucleus; Cytoplasm; Chromosome.
Tissue specificity: Expressed in colon, muscle, adrenal gland and peripheral blood lymphocytes.
Associated conditions: Beck-Fahrner syndrome (BEFAHRS).